GC
EW icon

Grimes & Company’s Edwards Lifesciences EW Stock Holding History

Grimes & Company’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Buy
+21,192
New +$1.78M 0.04% 200

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Grimes & Company's EW Position: Q2 2026 in Review

Grimes & Company opened a new position in Edwards Lifesciences (EW) in Q2 2026: 21,192 shares worth $1.92M. The stake represents 0.04% of the portfolio and ranks #200 among its holdings.

1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Grimes & Company held 21,192 shares of Edwards Lifesciences worth $1.92M as of Q2 2026.
  • Edwards Lifesciences was a new Grimes & Company position in Q2 2026.
  • Edwards Lifesciences made up 0.04% of Grimes & Company's portfolio in Q2 2026, its #200 holding.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.